Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, swinging from $52.66 to $176.66 (+235.47%) and finishing at $137.99 — a +151.16% period return and 68.78% of its range. Its 351.03% realized volatility against 73.36% implied produced the report's biggest vol surprise at 14.87x, meaning options were priced for a fraction of the move actually delivered. STIM (+72.86%, 8.29x) and TEM (+72.07%, 4.33x) show the same pattern of under-priced risk, as does EBS on the downside: -43.38% with realized 136.36% versus 80.76% implied (4.19x).

The opposite skew appears in the deep-IV small caps. CDXS (262.50% implied, 66.97% realized, 0.41x), DBVT (241.80%, 0.29x) and KPTI (182.81%, 0.70x) all carried triple-digit implied vol without delivering commensurate movement — options there looked expensive relative to outcome.

Closing position within range separates conviction from fade. GILD (80.87%), AMGN (79.44%), MRK (71.89%) and MGNX (72.54%) finished near highs. CVS closed at just 5.25% of its range after a -12.62% slide, with UNH (25.71%), KPTI (22.08%), DBVT (23.70%) and HIMS (20.63%) also giving back most of their advances.

Broader Market Context

Dispersion within the sector was extreme. The spread between MRNA (+235.47%) and EBS (-43.38%) is roughly 280 percentage points inside a single sector, which is far wider than any plausible sector-level beta could explain. Meanwhile, XLV — the sector proxy — gained 9.71% with realized vol of just 18.74%, and mega-cap names clustered tightly around it: JNJ +10.39%, ABBV +10.68%, ABT +12.61%, MRK +24.32%, AMGN +18.90%. That combination — a calm index and violently dispersed constituents — is the signature of idiosyncratic, single-name risk rather than a common sector shock.

Rotation vs. stock-specific moves. Several sub-groups pulled apart clearly:

• *Large-cap pharma/biotech* (LLY, MRK, AMGN, GILD, ABBV, JNJ, BMY) rose steadily with modest realized vol, mostly closing in the upper half of their ranges — consistent with defensive positioning or a broad bid for quality cash flows.
• *Managed care and services* diverged sharply: ELV +10.75%, HUM +13.98% and CI +8.70% advanced while UNH (-8.47%) and CVS (-12.62%) fell and closed near their lows. A split that wide within one business line is more consistent with company-level guidance or cost-trend concerns than with sector rotation.
• *Small/mid-cap biotech* (MRNA, STIM, QURE, MGNX, ANAB, CDXS, DBVT, KPTI, EBS) showed the largest vol ratios in both directions, typical of binary, event-driven outcomes.

Plausible backdrop. The pattern likely reflects a mix of drivers rather than one theme. Steady large-cap gains alongside a firm XLV are consistent with some defensive rotation into healthcare during a period of macro caution, while the biotech dispersion is more consistent with clinical, regulatory or approval-cycle catalysts that reprice individual names regardless of sector direction. Managed-care weakness in specific names could plausibly relate to ongoing scrutiny of medical cost trends, reimbursement policy or utilization — themes that periodically affect payers asymmetrically. Elevated implied vol in the small caps (CDXS, DBVT, KPTI above 180%) suggests the market was already pricing binary risk there, even where the realized move undershot. None of this is confirmable from the data alone; the numbers show dispersion and vol mispricing, not causes.